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rates, remission rates and discontinuation rates due to adverse events were extracted 
and compared in a Bayesian meta-analysis. RESULTS: Three aripiprazole, 2 quetiap-
ine and ﬁve olanzapine trials were identiﬁed together reporting on 2979 patients. 
Aripiprazole augmentation showed numerically higher efﬁcacy rates compared to 
quetiapine and olanzapine. Response odds ratios (95%CI) compared to quetiapine 
and olanzapine were 1.34(0.82–2.06) and 1.52(1.00–2.19) respectively. Remission 
odds ratios compared to quetiapine and olanzapine were 1.3(0.78–2.07) and 
1.26(0.77–1.92) respectively. Aripiprazole augmentation showed numerically lower 
discontinuation rates due to adverse events compared to quetiapine and olanzapine 
(OR = 0.99(0.24–2.62) and 0.77(0.23–1.89)). CONCLUSIONS: Amongst augmenta-
tion treatments with atypical antipsychotics in MDD, aripiprazole shows a tendency 
towards higher efﬁcacy rates and lower discontinuation rates due to adverse events 
compared to quetiapine and olanzapine. More direct head-to-head trials are needed 
to assess the comparative efﬁcacy and safety of adjunctive antipsychotics in MDD.
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OUTCOME TRAJECTORIES IN THE LONG-TERM TREATMENT OF 
SCHIZOPHRENIA
Milton D, Cuyun Carter G, Faries D, Ascher-Svanum H
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: This study aimed to determine distinct subgroups of schizophrenia 
patients based on their illness severity at baseline and characterize those who were 
most improved and those who worsened the most. METHODS: We used data from 
a large 3-year prospective, multi-site, observational non-interventional study of indi-
viduals treated for schizophrenia in the United States (US-SCAP). A hierarchical cluster 
analysis was performed to group the patients, using baseline clinical, functional, and 
resource utilization measures. Improvement of outcome was determined based on the 
distance from the deﬁned “worst baseline cluster” for each post-baseline measure. A 
trajectory analysis was used to group patients by improvement of outcome over the 
3-year study. RESULTS: Almost all participants (99% or 872/880) with 3-year data 
were found in a single outcomes trajectory, characterized by minimal changes from 
baseline cluster over the 3-year study period. Approximately one-fourth of individuals 
moved to a better outcome cluster while about 17% moved to a worse outcome cluster 
at each year. Only 4% of patients moved from the worst/next to worst cluster to the 
best/next to best cluster and 16.6% moved from the best/next to best cluster to the 
worst/next to worst cluster. Most improved patients were more likely than all other 
patients to have case management, to live in a supervised housing arrangement, and 
get assistance with securing social services and beneﬁts. CONCLUSIONS: The long-
term outcome trajectory for almost all schizophrenia patients in this 3-year naturalistic 
observational study was stable, devoid of change from the baseline cluster. Only a 
very small subgroup of patients experienced marked improvements, and they were 
more likely to be engaged in psychosocial rehabilitation. Although current ﬁndings 
may afﬁrm the value of psychosocial rehabilitation, results highlight the need to 
improve the relatively stagnant long-term illness trajectory of almost all chronically 
ill patients with schizophrenia.
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DISORDER; ANALYSES WITH THE RAMQ DATABASE
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OBJECTIVES: Approved treatments for attention-deﬁcit/hyperactivity disorder 
(ADHD) in Canada comprise short-acting (SA) and long-acting (LA) stimulants and 
a LA nonstimulant medication. The objective of this study was to elucidate different 
drug treatment patterns to treat ADHD in Canada. METHODS: A retrospective 
prescription claims analysis of a random sample of 15,838 ADHD patients from the 
Quebec provincial health plan (RAMQ) database was conducted. Any patient with 
≥1 physician claim with an ADHD diagnosis and a claim for a treatment approved 
for ADHD from July 2004 to June 2009 was considered. RESULTS: The mean age 
of the study sample was 14.0 years (SD = 8); 72.6% of the sample were males. There 
were a total of 416,646 ADHD prescriptions during the 5-year study period. As a 
proportion of total prescriptions, use of SA medications declined from 72.83% in 
2004 to 26.38% in 2009, while use of stimulant and nonstimulant LA medications 
increased from 27.17% to 73.62% over the same period. Approximately half of the 
patients used both SA and LA medications either concomitantly or subsequently while 
approximately 30% used only SA and 19% used only LA. Among those patients who 
used both types of formulations, switching from SA to LA was the most frequent 
(27.9%) treatment pattern. A greater proportion of patients (6.4%) on LA methyl-
phenidates required augmentation with SA medications when compared with those 
on LA amphetamines (1.9%; p < 0.01). CONCLUSIONS: Results of this RAMQ 
database analysis illustrate that over time, patients shifted from the use of SA stimu-
lants to formulations that provide all-day coverage. Switching from SA to LA medica-
tions and augmentation of LA medications with SA medication are common treatment 
patterns observed in the management of ADHD with implications for patient care and 
the efﬁcient use of health care resources. Supported by funding from Shire Develop-
ment Inc.
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OBJECTIVES: The purpose of the review was to evaluate the efﬁcacy and safety of 
escitalopram compared with sertraline and venlafaxine in treatment of major depres-
sive disorder (MDD). METHODS: The analysis was performed in accordance with 
the rules of systematic review, based on Cochrane Collaboration guidelines and recom-
mendations of Health Technology Assessment Agency in Poland (AOTM). RESULTS: 
In this report there were two subanalyses conducted, evaluating the efﬁcacy and safety 
of escitalopram in comparison with sertraline and venlafaxine, both consisted of two 
multicenter, parallel-group, double-blinded, randomized clinical trials. In both com-
parisons efﬁcacy was evaluated, based on the mean changes in MADRS, HAM-D, 
CGI-S, CES-D, HAM-A and CGI-I grading scales, as well as safety analysis was 
performed. Period of eight weeks treatment with escitalopram and sertraline as well 
as venlafaxine resulted in decrease in number of MDD symptoms and quality of life 
improvement. Over 50% decrease in number of major depression symptoms in 
MADRS and HAM-D grading scales compared to baseline indicates high clinical 
relevance of obtained results, even though statistical signiﬁcance was not reached. 
Safety analysis showed similar safety proﬁles of all drugs taken into account. There 
were no statistical differences between populations in any of primary endpoints, except 
for withdrawals from the study due to adverse events in comparison of escitalopram 
vs venlafaxine favoring escitalopram. CONCLUSIONS: Escitalopram seems to be 
equally efﬁcient and safe drug as sertraline and venlafaxine in treatment of patients 
with MDD. The clinical-effectiveness analysis ascertained equivalence of efﬁcacy and 
similarity of safety proﬁle of escitalopram in comparison with sertraline and venla-
faxine in therapy of patients with MDD.
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OBJECTIVES: In pharmaceutical outcomes research using health care claims data-
bases, periods during which patients are hospitalized have constituted “black holes”, 
as these databases do not contain any information on pharmacotherapy received in 
hospital. While admission-level databases provide such information, they lack infor-
mation on pharmacotherapy received outside of hospital. Recently, it has become 
possible to link these two types of databases. In this study, we explored their potential 
value to outcomes research, focusing attention on second-generation antipsychotic 
(SGA) treatment before, during, and after hospitalization for schizophrenia. 
METHODS: Using a linked inpatient/outpatient database, we identiﬁed all adults with 
≥1 admissions for schizophrenia between January 1, 2001 and September 30, 2008. 
Focusing on each patient’s ﬁrst admission, we compiled all health care claims during 
the 6-month periods preceding and following hospitalization. As our interest was in 
the use of SGAs, our scope was limited to patients with evidence of receipt of oral 
ziprasidone, aripiprazole, or quetiapine (“study agents”) immediately preceding hos-
pital discharge. We then examined receipt of these agents during the 6-month periods 
preceding hospitalization and following hospital discharge based on outpatient phar-
macy claims; receipt of study agents in hospital was examined using admission-level 
data. Adherence with study agents following hospital discharge was assessed using 
proportion of days covered (PDC); patients were deemed nonadherent if PDC fell 
below 80%. RESULTS: A total of 43 patients were identiﬁed who met all study entry 
criteria. Twenty-four patients (56%) had evidence of receipt of a study agent in the 
period preceding hospitalization. While all patients had evidence of receipt of study 
agents following hospital discharge, only 12% were adherent at 6 months. CONCLU-
SIONS: Linked inpatient/outpatient databases are a promising avenue for future 
pharmaceutical outcomes research, as they may greatly expand understanding of the 
complete chronology of pharmacotherapy–and associated outcomes–for many disease 
conditions.
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OBJECTIVES: To examine prevalence and predictors of anticholinergic medication 
use in elderly nursing home residents with dementia. METHODS: The study evaluated 
anticholinergic medication use in elderly (>= 65 years) nursing home residents using 
the 2004 National Nursing Home Survey (NNHS). Anticholinergic Drug Scale was 
used to classify medications as Level 1, Level 2 or Level 3 in order of their increasing 
anticholinergic activity. Descriptive weighted analysis was used to determine the 
prevalence of anticholinergic medication use in elderly dementia patients. Multinomial 
logistic regression within the conceptual framework of Andersen Behavioral Model 
(ABM) was used to examine the predictors associated with each level of anticholinergic 
medication use as well as concurrent use of anticholinergic medications belonging to 
two or more levels. RESULTS: According to the NNHS, 0.51 million (95% CI-0.49–
0.53) or 73.62% (72.23–75.00) of the elderly patients with dementia used anticho-
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linergic medications. The highest prevalence was seen for Level 1 medications 
(52.37%) followed by Level 2 (3.02%) and Level 3 (2.31%) medications. The preva-
lence of concurrent use of anticholinergic medications of various levels was 8.42% 
(7.53–9.32). Multinomial regression analysis revealed that predisposing (age) and need 
(behavioral symptoms, activities of daily living, out of bed mobility and depression) 
factors were positively associated with Level 1 drug use. Need factors (behavioral 
symptoms and total number of medications taken) were found to be negatively associ-
ated with Level 2 drug use whereas need factors like parkinsonism and depression 
were positively associated with receiving Level 3 medications and concurrent use, 
respectively. CONCLUSIONS: Nearly three of four elderly nursing home residents 
with dementia received anticholinergic medications of different levels. The ﬁndings 
suggest that there is a need to optimize anticholinergic medications in dementia 
patients, especially the higher level agents due to their signiﬁcant adverse proﬁle in 
dementia patients.
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OBJECTIVES: Individuals with a serious mental illness (SMI) often experience recidi-
vistic patterns in the criminal justice system (CJS). It has been argued that the provision 
of mental health services can disrupt this pattern. We examined the impact of com-
munity based mental health services on the arrest patterns of adults with a SMI who 
became involved in the CJS in Pinellas County Florida and Harris County Texas. 
METHODS: We identiﬁed adults 18–64 years old in Florida and Texas with a SMI 
who spent at least one day in jail during an index year. Statewide and local administra-
tive data sets were used to document their patterns of arrests and utilization of health 
and mental health services over 3–4 year periods. Generalized estimating equations 
were used for count data to estimate the association of outpatient and ER/inpatient 
mental health contacts in a quarter and arrests in the subsequent quarter. Individual 
ﬁxed effects models were also estimated to account for unobserved time invariant 
factors correlated with treatment and the likelihood of arrest. RESULTS: We identiﬁed 
3769 and 8505 individuals in the Florida and Texas data sets respectively. In Florida, 
individuals receiving outpatient services in a quarter were 20% less likely to be 
arrested in the subsequent quarter. The effect was greater for misdemeanor than for 
felony arrests. Individuals receiving ER/inpatient services were 7% more likely to be 
arrested in the subsequent quarter, and 13% more likely to have a felony arrest. The 
association between outpatient mental health services and arrests was conﬁrmed by 
the individual ﬁxed effects model. Parallel analyses are underway using Texas data to 
determine if the relationships hold for different jurisdictions and time frames. 
CONCLUSIONS: Outpatient mental health services were associated with a decrease 
in the risk of arrests among groups of individuals with a SMI and criminal justice 
involvements.
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OBJECTIVES: Optimal treatment of major depressive disorder (MDD) includes the 
selection of an adequate antidepressant medication and its delivery at a fully thera-
peutic dose for adequate treatment duration. Many factors may inﬂuence a physician’s 
decision making with respect to antidepressant choice and appropriate dose level. This 
study examined the pretreatment predictors of high-dose prescription of duloxetine 
for MDD patients in the real world clinical setting. METHODS: In a large commercial 
managed-care claims database, 6,132 MDD patients, who were initiated on duloxetine 
between July 1, 2005 and June 30, 2006, had no prior prescription of duloxetine for 
6 months, and had continuous enrollment for both 12 months prior to and post initia-
tion, were included. The associations between demographics and pre-initiation clinical 
variables and the maximum prescribed duloxetine dose (high: > 60 mg/day; mid: 
60 mg/day) were examined by chi-square tests and logistic regression. RESULTS: Of 
the sample, 16.3% had a maximum prescribed duloxetine dose of less than 60 mg/
day; 59.3%, 60 mg/day; and 24.4%, >60 mg/day. Compared with mid-dose patients, 
high-dose patients were older; had more comorbidities of neuropathic pain, osteoar-
thritis, ﬁbromyalgia, drug dependence, and bipolar disorders; were more likely to be 
treated by psychiatrists; used more benzodiazepines, venlafaxine, atypical antipsychot-
ics, psychostimulants, and anticonvulsants; and had higher pharmacy and medical 
costs in the prior 1 year (All p values < .05). After adjustment for health plan type 
and geographic region of residence, the following factors were independently associ-
ated with high-dose prescription: older age (36–64 vs. 18–35 years, OR = 1.34–1.53), 
neuropathic pain (OR = 1.56), prior use of psychostimulants (OR = 1.32), benzodi-
azepines (OR = 1.22), venlafaxine (OR = 1.24), atypical antipsychotics (OR = 1.35), 
and physician specialty (psychiatrist vs. non-psychiatrist, OR = 1.54). CONCLU-
SIONS: Multiple demographic and clinical characteristics and prior costs are associ-
ated with a high-dose duloxetine prescription. High-dose treated patients may 
represent a group of complicated patients with high medical costs who need intensive 
treatment.
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DISORDER (BD)-RELATED RE-HOSPITALIZATIONS AMONG PATIENTS 
WITH MANIC OR MIXED BD EPISODES
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OBJECTIVES: Bipolar disorder (BD) treatment guidelines state that antidepressants 
(ADs) may precipitate, or exacerbate manic or mixed episodes and generally recom-
mend tapering or discontinuing ADs for patients with recent acute manic or mixed 
episodes. This study assessed the association between continued AD use and BD-
related re-hospitalizations among BD patients. METHODS: Using the PharMetrics 
Patient-Centric Database from January 1, 2004–June 30, 2007, we identiﬁed adults 
with an acute psychiatric event (“index event”), deﬁned by hospitalizations, emergency 
room visits, or physician visits with a prescription for a new BD medication with a 
primary diagnosis of BD I mania or BD I mixed. All patients were required to be 
eligible for the 12 months before and after index event and have a BD-related hospi-
talization (any diagnosis of any BD subtype) in the pre-index period. Patients with 
schizophrenia at any time during the study period were excluded. Continued AD use 
was deﬁned using prescription drug claims as 30+ days of available AD therapy within 
120 days after the index event. Logistic regression—controlling for age, sex, geo-
graphic region, baseline comorbidities—was used to determine the association 
between continued AD use and post-index BD-related re-hospitalizations (any diag-
nosis of any BD subtype). RESULTS: A total of 2126 patients met study criteria (mean 
age, 44; 57% female). 433 BD patients (20.4%) were re-hospitalized within 1 year. 
Patients receiving continued AD therapy (31.5%) were signiﬁcantly more likely to be 
re-hospitalized (OR, 1.387; 95% CI, 1.102, 1.748) than those without continued use. 
Other predictors of increased risk of re-hospitalization included being female and 
baseline diagnoses of comorbid substance abuse and eating disorders. CONCLU-
SIONS: Continued AD use in manic or mixed BD may be inappropriate. In this study, 
AD use for 30+ days within 120 days after an acute episode was associated with 
greater risk of BD-related re-hospitalization.
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OBJECTIVES: To evaluate risk and predictors of hospitalization among commercially 
insured patients with bipolar I disorder. METHODS: Retrospective cohort analysis 
using the PharMetrics Patient-centric Database, including patients with ≥1 inpatient 
or ≥2 outpatient medical claims indicating bipolar I disorder and ≥1 prescription for 
an antipsychotic medication between 7/1/2005, and 3/31/2007. Patients were followed 
1 year from date of ﬁrst (index) antipsychotic prescription. Continuous health beneﬁt 
eligibility from 1 year before (baseline) through 1 year after (follow-up) index was 
required. Patients had to receive ≥1 additional antipsychotic claim during follow-up 
to ensure a treated population. Adherence was measured using medication possession 
ratio (number of outpatient-treated days divided by total number of outpatient days 
during follow-up). Multivariate logistic regressions were used to identify factors asso-
ciated with all-cause (AC) and psychiatric-related (PR) hospitalization. RESULTS: A 
total of 12,100 patients were eligible. Mean (±SD) patient age was 37.2 (±15.7) years, 
59.9% were female; 22.8% had baseline diagnoses of substance abuse, and 49.8% 
had other psychiatric conditions. During follow-up, 27.9% of patients had AC and 
25.3% had PR hospitalizations. On average (±SD), patients had 0.5 (±1.1) AC and 
0.4 (±1.0) PR hospitalizations. Baseline substance abuse or diagnosis of other psycho-
sis; use of antidepressants, anxiolytics, or anticholinergics; psychiatric hospitalization; 
and nonadherence to antipsychotic therapy during follow-up were associated with 
signiﬁcantly greater risk (P < 0.05) of AC and PR hospitalizations; age < 35 years was 
also associated with signiﬁcantly greater risk of PR hospitalization. Baseline anticon-
vulsant use was associated with signiﬁcantly lower risk of PR hospitalization. CON-
CLUSIONS: Several patient characteristics appeared to be associated with greater risk 
of hospitalization among commercially insured bipolar I patients receiving antipsy-
chotics. These ﬁndings may be useful to health plan administrators interested in tar-
geted interventions, though further research on the impact of such interventions is 
needed. Supported by funding from Ortho-McNeil Janssen Scientiﬁc Affairs, LLC.
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A COMPARISON OF TRANSITIONS BETWEEN HEALTH STATES AND 
INSTITUTIONALIZATION AMONG ALZHEIMER’S DISEASE PATIENTS 
VERSUS NON-ALZHEIMER’S DISEASE DEMENTIA PATIENTS USING THE 
NACC-UDS DATABASE
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OBJECTIVES: Compare transitions between mild, moderate and severe health states, 
and to death or institutionalization for Alzheimer disease (AD) and non-AD dementia 
patients. METHODS: The National Alzheimer Coordinating Center’s Uniform Data 
Set (NACC-UDS) is a large, longitudinal dataset funded by the National Institute of 
Aging that includes AD and non-AD dementia patients, and non-demented controls. 
